Vaccine-induced antibody responses in patients with carcinoma

References

• Finn OJ. Cancer immunology. N. Engl. J. Med.358, 2704–2715 (2008).
   PubMed Web of Science ®Google Scholar
• Old LJ. Cancer vaccines: an overview. Cancer Immunity8(Suppl. 1), 1–4 (2008).
   PubMedGoogle Scholar
• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol.90, 1–50 (2006).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Ragupathi G, Musselli C. Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J. Clin. Immunol.20(2), 85–93 (2000).
   PubMedGoogle Scholar
• Morris LF, Ribas A. Therapeutic cancer vaccines. Surg. Oncol. Clin. N. Am.16, 81–831 (2007).
   PubMedGoogle Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother.54, 721–728 (2005).
   PubMed Web of Science ®Google Scholar
• Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev.222, 129–144 (2008).
   PubMed Web of Science ®Google Scholar
• King C. New insights into the differentiation and function of T follicular helper cells. Nature Rev. Immunol.9, 757–766 (2009).
   PubMed Web of Science ®Google Scholar
• Malo KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat. Immunol.2, 816–822 (2001).
   PubMedGoogle Scholar
• Piersmaa SJ, Weltersb MJP, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Human Immunol.69, 241–249 (2008).
   PubMedGoogle Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol.25, 267–296 (2007).
   PubMed Web of Science ®Google Scholar
• Zwirner NW, Croci DO, Domaica CI, Rabinovich GA. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr. Pharm. Des.16(3), 255–267 (2010).
   PubMedGoogle Scholar
• Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses: Independent forces or collaborators in he fight against cancer? Curr. Opin. Investig. Drugs2(1), 133–135 (2001).
   PubMedGoogle Scholar
• Ragupathi G, Gathuru J, Livingston PO. Antibody inducing polyvalent cancer vaccines. Cancer Treat. Res.123, 157–180 (2005).
   PubMedGoogle Scholar
• Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nature Rev. Cancer4, 448–456 (2004).
   PubMed Web of Science ®Google Scholar
• Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature450, 903–907 (2007).
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA92, 11810–11813 (1995).
   PubMed Web of Science ®Google Scholar
• Minenkova O, Pucci A, Pavoni E et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int. J. Cancer106(4), 534–544 (2003).
   PubMedGoogle Scholar
• Jäger D, Taverna C, Zippelius A, Knuth A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol. Immunother.53(3), 144–147 (2004).
   PubMed Web of Science ®Google Scholar
• Desmetz C, Maudelonde T, Mangé A, Solassol J. Identifying autoantibody signatures in cancer: a promising challenge. Expert. Rev. Proteomics6(4), 377–386 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidlin H, Diehl SA, Blom B. New insights into the regulation of human B-cell differentiation. Trends Immunol.30(6), 277–285 (2009).
   PubMed Web of Science ®Google Scholar
• Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol.10, 385–393 (2009).
   PubMed Web of Science ®Google Scholar
• Ettinger R, Sims GP, Fairhurst AM et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol.175(12), 7867–7879 (2005).
   PubMed Web of Science ®Google Scholar
• Bryant VL Zwirner NW, Croci DO, Domaica CI, Rabinovich GA. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J. Immunol.179(12), 8180–8190 (2007).
   PubMed Web of Science ®Google Scholar
• Kuchen S. Robbins R, Sims GP et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell–B cell collaboration. J. Immunol.179(9), 5886–5896 (2007).
   PubMed Web of Science ®Google Scholar
• Maruyama M, Lam KP, Rajewsky K. Memory B cell persistence is independent of persisting immunizing antigen. Nature407, 636–642 (2000).
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science298, 2199–2202 (2002).
   PubMed Web of Science ®Google Scholar
• Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet373, 1033–1040 (2009).
   PubMed Web of Science ®Google Scholar
• Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Devel. Ther.3, 7–16 (2009).
   PubMed Web of Science ®Google Scholar
• Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer93, 97–106 (2001).
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Frödin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res.10, 3273–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol.174(9), 5706–5712 (2005).
   PubMed Web of Science ®Google Scholar
• Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity6, 655–661 (1997).
   PubMed Web of Science ®Google Scholar
• Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett.257(1), 47–55 (2007).
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer94, 259–267 (2006).
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv. Immunol.96, 179–204 (2007).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99, 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortes B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol.26, 1789–1796 (2008).
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol.22, 4717–4724 (2004).
   PubMed Web of Science ®Google Scholar
• Niwa R, Hatanaka S, Shoji-Hosaka E et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin. Cancer Res.10, 6248–6255 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki E, Niwa R, Saji S et al. A nonfucosylated anti-HER2 antibody augments antibody dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res.13, 1875–1882 (2007).
   PubMed Web of Science ®Google Scholar
• Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci.100(9), 1566–1572 (2009).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene27, 161–167 (2008).
   PubMed Web of Science ®Google Scholar
• Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res.67(17), 7945–7947 (2007).
   PubMed Web of Science ®Google Scholar
• Moreno M, Mol BM, von Mensdorff-Pouilly S et al. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Lett.272(1), 70–76 (2008).
   PubMedGoogle Scholar
• Liljefors M, Nilsson B, Mellstedt H, Frödin JE. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother.57(3), 379–388 (2008).
   PubMed Web of Science ®Google Scholar
• Carson WE, Parihar R, Lindemann MJ et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol.31, 3016–3025 (2001).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Kono K, Kawaguchi Y et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br. J. Cancer102(3), 520–529 (2010).
   PubMedGoogle Scholar
• Kono K, Takahashi A, Ichira F, Sugai H, Akaike H, Fujii H. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res.62, 5813–5817 (2002).
   PubMed Web of Science ®Google Scholar
• Wang G, Tschoi M, Spolski R et al.In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res.63, 9016–9022 (2003).
   PubMed Web of Science ®Google Scholar
• Davis ID, Skrumsager BK, Cebon J et al. An open-label, two-arm, Phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res.13(12), 3630–3636 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson JA, Curti BD, Redman BG et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol.26(12), 2034–2039 (2008).
   PubMed Web of Science ®Google Scholar
• Frederiksen KS, Lundsgaard D, Freeman JA et al. IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother.57(10), 1439–1449 (2008).
   PubMed Web of Science ®Google Scholar
• Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a Phase IIa trial. Clin. Cancer Res.15(6), 2123–2129 (2009).
   PubMed Web of Science ®Google Scholar
• Dodds MG, Frederiksen KS, Skak K et al. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol. Immunother.58(6), 843–854 (2009).
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of two parts. N. Engl. J. Med.344(14), 1058–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N. Engl. J. Med.344(15), 1140–1144 (2001).
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res.20, 34–50 (2010).
   PubMed Web of Science ®Google Scholar
• Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol.40, 109–123 (2003).
   PubMed Web of Science ®Google Scholar
• Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv. Exp. Med. Biol.632, 159–174 (2008).
   PubMed Web of Science ®Google Scholar
• Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol. Immunol.46(14), 2794–2800 (2009).
   PubMed Web of Science ®Google Scholar
• Xu C, Jung M, Burkhardt M et al. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate62, 224–232 (2005).
   PubMedGoogle Scholar
• Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother.55, 973–980 (2006).
   PubMedGoogle Scholar
• Bjorge L, Hakulinen J, Vintermyr OK et al. Ascitic complement system in ovarian cancer. Br. J. Cancer92, 895–905 (2005).
   PubMedGoogle Scholar
• Fishelson Z, Hochman I, Greene LE, Eisenberg E. Contribution of heat shock proteins to cell protection from complement-mediated lysis. Int. Immunol.13, 983–991 (2001).
   PubMed Web of Science ®Google Scholar
• Pilzer D, Fishelson Z. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int. Immunol.17, 1239–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Sreedhar AS, Nardai G, Csermely P. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors. Immunol. Lett.92, 157–161 (2004).
   PubMedGoogle Scholar
• Burchell J, Poulsom R, Hanby A et al. An α2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology9, 1307–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Natsume A, In M, Takamura H et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res.68(10), 3863–3872 (2008).
   PubMed Web of Science ®Google Scholar
• Macor P, Tripodo C, Zorzet S et al.In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res.67, 10556–10563 (2007).
   PubMed Web of Science ®Google Scholar
• Carroll MC. The complement system in regulation of adaptive immunity. Nat. Immunol.5(10), 981–986 (2004).
   PubMed Web of Science ®Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science272, 50–54 (1996).
   PubMed Web of Science ®Google Scholar
• Fang Y, Xu C, Fu Y, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol.160, 5273–5279 (1998).
   PubMed Web of Science ®Google Scholar
• Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte containing complement receptor type 2 and CD19. J. Exp. Med.173, 55–64 (1991).
   PubMed Web of Science ®Google Scholar
• Barrington RA, Zhang M, Zhong X et al. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J. Immunol.175, 2859–2867 (2005).
   PubMed Web of Science ®Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.27(34), 5838–5847 (2009).
   PubMed Web of Science ®Google Scholar
• Capdevila J, Elez E, Macarulla T et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer. Treat. Rev.35, 354–363 (2009).
   PubMedGoogle Scholar
• Wesseling J, Van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol.129, 255–265 (1995).
   PubMed Web of Science ®Google Scholar
• Hilkens J, Wesseling J, Vos HL et al. Involvement of the cell-surface bound mucin, episialin/MUC1, in progression of human carcinomas. Biochem. Soc. Trans.23, 822–826 (1995).
   PubMedGoogle Scholar
• Kondo K, Kohno N, Yokoyama A, Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res.58, 2014–2019 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang K, Baeckström D, Brevinge H, Hansson GC. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis A and X epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J. Cell Biochem.60(4), 538–549 (1996).
   PubMed Web of Science ®Google Scholar
• Zhang K, Sikut R, Hansson GC. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell. Immunol.176(2), 158–165 (1997).
   PubMed Web of Science ®Google Scholar
• Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res.56, 4244–4249 (1996).
   PubMed Web of Science ®Google Scholar
• Rahn JJ, Chow JW, Horne GJ et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metastasis22, 475–483 (2005).
   PubMed Web of Science ®Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl Acad. Sci. USA103(24), 9190–9195 (2006).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother.25(2), 97–138 (2002).
   PubMed Web of Science ®Google Scholar
• Hornbeck P. Enzyme-linked immunosorbent assays. Curr. Protoc. Immunol.2, 2.1 (2001).
   Google Scholar
• von Mensdorff-Pouilly S, Vennegoor C, Hilgers J. Detection of humoral immune responses to mucins. Methods Mol. Biol.125, 495–500 (2000).
   PubMedGoogle Scholar
• von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol.19(3), 186–195 (1998).
   PubMed Web of Science ®Google Scholar
• Oei ALM, Moreno M, Verheijen RHM et al. Induction of IgG antibodies to MUC1 is associated with improved survival in patients with epithelial ovarian cancer. Int. J. Cancer123(8), 1848–1853 (2008).
   PubMedGoogle Scholar
• Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol. Immunother.57, 285–288 (2008).
   PubMedGoogle Scholar
• Hornbeck P, Fleisher TA, Papadopoulos NM. Isotype determination of antibodies. Curr. Protoc. Immunol.2, 2.2 (2001).
   PubMedGoogle Scholar
• von Mensdorff-Pouilly S, Petrakou E, Kenemans P et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer86(5), 702–712 (2000).
   PubMed Web of Science ®Google Scholar
• Vennegoor CJ, Nijman HW, Drijfhout JW et al. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett.116(1), 93–101 (1997).
   PubMedGoogle Scholar
• Schol DJ, Meulenbroek MF, Snijdewint FG et al. ‘Epitope fingerprinting’ using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumour Biol.19(Suppl. 1), 35–45 (1998).
   PubMedGoogle Scholar
• von Mensdorff-Pouilly S, Kinarsky L, Engelmann K et al. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology15(8), 735–746 (2005).
   PubMedGoogle Scholar
• Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISpot) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods65, 109–121 (1983).
   PubMed Web of Science ®Google Scholar
• Mashishi T, Gray CM. The ELISpot assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin. Chem. Lab. Med.40(9), 903–910 (2002).
   PubMed Web of Science ®Google Scholar
• Janetzki S, Panageas KS, Ben-Porat L et al. Results and harmonization guidelines from two large-scale international ELISpot profficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer. Immunol. Immunother.57(3), 303–315 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson DL, Kurman CC, Serbousek DE. 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC). Curr. Protoc. Immunol.7, 7.27 (2001).
   Google Scholar
• Gilewski T, Ragupathi G, Bhuta S et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a Phase I trial. Proc. Natl Acad. Sci. USA98(6), 3270–3275 (2001).
   PubMed Web of Science ®Google Scholar
• Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res.67(4), 1842–1852 (2007).
   PubMed Web of Science ®Google Scholar
• Mishima Y, Sugimura N, Matsumoto-Mishima Y et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin. Cancer Res.15(10), 3624–3632 (2009).
   PubMedGoogle Scholar
• Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert. Rev. Vaccines7(7), 963–975 (2008).
   PubMed Web of Science ®Google Scholar
• Kiessling A, Fϋssel S, Wehner R et al. Advances in specific immunotherapy for prostate cancer. Eur. Urology53, 694–708 (2008).
   PubMedGoogle Scholar
• Palma M, Choudhury A, Mellstedt H. Cancer vaccines for non-small-cell lung cancer. Minerva Chir.64(6), 643–653 (2009).
   PubMedGoogle Scholar
• Hanisch FG. Design of a MUC1-based cancer vaccine. Biochem. Soc. Trans.33, 705–708 (2005).
   PubMed Web of Science ®Google Scholar
• Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene22, 6570–6578 (2003).
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyib GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist14, 320–368 (2009).
   PubMed Web of Science ®Google Scholar
• Disis ML, Calenoff E, McLaughlin G et al. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res.54, 16–20 (1994).
   PubMed Web of Science ®Google Scholar
• Ward RL, Hawkins NJ, Coomber D et al. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum. Immunol.60, 510–515 (1999).
   PubMed Web of Science ®Google Scholar
• Bernhard H, Salazar L, Schiffman K et al. Vaccination against the HER-2/neu oncogenic protein. Endocr. Relat. Cancer9, 33–44 (2002).
   PubMed Web of Science ®Google Scholar
• Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol.24(5), 571–578 (2004).
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K, Guthrie K et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. J. Clin. Oncol.22(10), 1916–1925 (2004).
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika A, Osada T et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J. Transl. Med.5, 42 (2007).
   PubMed Web of Science ®Google Scholar
• Kaumaya PT, Foy KC, Garrett J et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J. Clin. Oncol.27(31), 5270–5277 (2009).
   PubMed Web of Science ®Google Scholar
• Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci.100(11), 2014–2021 (2009).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4+ T-cell responses to MAGE-3 protein in lung cancer patients. J. Immunol.172, 3289–3296 (2004).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Cao Y et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl Acad. Sci. USA105, 1650–1655 (2008).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage Ib/II non-small cell lung cancer (NSCLC). J. Clin. Oncol.25(18 Suppl.), S398 (2007).
   Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever Phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer10(5), 371–374 (2009).
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res.95, 1–30 (2006).
   PubMed Web of Science ®Google Scholar
• Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA94, 1914–1918 (1997).
   PubMed Web of Science ®Google Scholar
• Bender A, Karbach J Neumann A et al. LUD 00–009: Phase I study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive atients with NY-ESO-1-expressing cancer. Cancer Immunity7, 16 (2007).
   PubMedGoogle Scholar
• Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: association with survival. Int. J. Cancer126, 909–918 (2010).
   PubMed Web of Science ®Google Scholar
• Odunsi K, Qian F, Matsuzaki J et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA104, 12837–12842 (2007).
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ Tcell responses in humans. Proc. Natl Acad. Sci. USA101, 10697–10702 (2004).
   PubMed Web of Science ®Google Scholar
• Chen Q, Jackson H, Parente P et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl Acad. Sci. USA101, 9363–9368 (2004).
   PubMed Web of Science ®Google Scholar
• Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA104, 8947–8952 (2007).
   PubMed Web of Science ®Google Scholar
• Kawabata R, Wada H, Isobe M et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int. J. Cancer120(10), 2178–2184 (2007).
   PubMed Web of Science ®Google Scholar
• Aoki M, Ueda S, Nishikawa H et al. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine27(49), 6854–6861 (2009).
   PubMed Web of Science ®Google Scholar
• Jager E, Karbach J, Gnjatic S et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA103, 14453–14458 (2006).
   PubMed Web of Science ®Google Scholar
• Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA105, 20410–20415 (2008).
   PubMed Web of Science ®Google Scholar
• Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J. Clin. Lab. Anal.5, 344–366 (1991).
   PubMed Web of Science ®Google Scholar
• Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J. Clin. Oncol.20, 2197–2207 (2002).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol.23(4), 720–731 (2005).
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers15(4), 343–356 (2000).
   PubMed Web of Science ®Google Scholar
• Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem.265, 15286–15293 (1990).
   PubMed Web of Science ®Google Scholar
• Burchell J, Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with coreprotein epitopes of the MUC1 gene product. Epithelial Cell Biol.2, 155–162 (1993).
   PubMedGoogle Scholar
• Karsten U, von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen? Tumour Biol.26(4), 217–220 (2005).
   PubMed Web of Science ®Google Scholar
• Ionnanides CG, Fisk B, Jerome KR et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol.151, 693–703 (1993).
   Google Scholar
• von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol.18, 574–583 (2000).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Hu XF, Pouniotis DS, Xing PX. MUC1: a molecule of many talents. Curr. Trends Immunol.12, 629–639 (2004).
   Google Scholar
• Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res.6, 1693–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Ragupathi G, Hood C et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res.13, 4170–4177 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang HS, Cordon-Cardo C et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int. J. Cancer73(1), 50–56 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang S, Cordon-Cardo C, Zhang HS et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer73(1), 42–49 (1997).
   PubMed Web of Science ®Google Scholar
• Holmberg LA, Sandmaier BM. Vaccination with theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines3(6), 655–663 (2004).
   PubMedGoogle Scholar
• Braun DP, Crist KA, Shaheen F, Staren ED, Andrews S, Parker J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am. J. Surg.190(4), 570–571 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu J, Warren JD, Danishefsky SJ. Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan–Kettering experience Expert Rev. Vaccines8(10), 1399–1413 (2009).
   PubMed Web of Science ®Google Scholar
• Gilewski TA, Ragupathi G, Dickler et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res.13(10), 2977–2985 (2007).
   PubMed Web of Science ®Google Scholar
• Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized Phase III studies with active cancer immunotherapies – outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC). Vaccine25S, B97–B109 (2007).
   Google Scholar
• Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother.30(1), 1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, Day S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.15(23), 7412–7420 (2009).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities Vaccine25S, B89–B96 (2007).
   Google Scholar
• Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res.15(17), 5323–5337 (2009).
   PubMed Web of Science ®Google Scholar
• Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer103, 97–100 (2003).
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am. J. Respir. Crit. Care Med.161, 589–594 (2000).
   PubMed Web of Science ®Google Scholar
• Fagerberg J, Hjelm AL, Ragnhammar P, Frödin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res.55, 1824–1827 (1995).
   PubMed Web of Science ®Google Scholar
• de Bono JS, Rha SY, Stephenson J et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol.15, 1825–1833 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor C, Hershman D, Shah N et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res.13, 5133–5143 (2007).
   PubMed Web of Science ®Google Scholar
• Hudis AC. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357, 39–51 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature438, 967–974 (2005).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol.12, 1036–1044 (1994).
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Gupta RK, Qi K et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol.16, 2913–2920 (1998).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Johnson TD, Nishinaka Y et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol.112, 205–209 (1999).
   PubMed Web of Science ®Google Scholar
• Taylor S, Zhou J, Park J et al. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favourable clinical outcomes without autoimmunity. Clin. Cancer Res.14(12), 3896–3905 (2008).
   PubMedGoogle Scholar
• Bon GG, van Kamp GJ, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Kenemans P. Quantification of MUC1 in breast cancer patients. A method comparison study. Eur. J. Obstet. Gynecol. Reprod Biol.83(1), 67–75 (1999).
   PubMed Web of Science ®Google Scholar
• Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, Kenemans P. CA125: fundamental and clinical aspects. Semin. Cancer Biol.9, 117–124 (1999).
   PubMedGoogle Scholar
• Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19–19 as tumor marker in patients with pancreatic cancer. Oncology70(4), 255–264 (2006).
   PubMedGoogle Scholar
• Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol.18(1), 15–24 (2009).
   PubMed Web of Science ®Google Scholar
• Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu. Rev. Med.60, 139–151 (2009).
   PubMedGoogle Scholar